NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Andrew D. Zelenetz, Leo I. Gordon, Julie Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Lihua E. Budde, Paolo F. Caimi, Sven de Vos, Bhagirathbhai Dholaria, Bita Fakhri, Luis Fayad, Martha Glenn, Thomas M. Habermann, Francisco J. Hernandez‐Ilizaliturri, Eric D. Hsi, Boyu Hu, Mark Kaminski, Chris R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Megan S. Lim, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph M. Tuscano, Julie M. Vose, Mary A. Dwyer, Hema Sundar
Abstract
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.